Antiviral antibacterial inorganic interior wall coating and preparation method thereof

Abstract

The invention provides an antiviral antibacterial inorganic interior wall coating which comprises the following components in parts by mass: 20-40 parts of silica sol and 0.8-1.5 parts of an antiviral antibacterial preservative. According to the invention, the specific antiviral and bactericidal preservative is introduced into the coating, and the triazole compound, the isothiazolinone compound, the thio-pyridine oxide compound and the chlorinated hydroxydiphenyl ether compound in the antiviral and bactericidal preservative can play a synergistic effect; the coating has excellent antiviral and antibacterial activity, durability and alkali resistance; and silica sol is reasonably compounded with the antiviral bactericidal preservative, so that the antiviral bactericidal preservative gives full play to performance advantages of the antiviral bactericidal preservative, and the coating is endowed with good uniformity and stability.

Description

Technical Field

[0001] The invention belongs to the technical field of coatings, and in particular relates to an antiviral and antibacterial inorganic interior wall coating and a preparation method thereof. Background Art

[0002] There are various viruses and bacteria in the environment, especially in crowded places such as hospitals and shopping malls, where the virus and bacteria content is higher. People are prone to bacterial or viral infections when they come into contact with contaminated surfaces, especially for some special groups with poor resistance, who are more likely to get bacterial or viral infections after coming into contact with contaminated surfaces. In addition, with the improvement of people's health and protection awareness, the demand for antiviral and antibacterial coating products in places such as homes, hospitals, and shopping malls is increasing. However, the antiviral or antibacterial properties of existing antiviral or antibacterial coatings are average, and the antiviral or antibacterial properties are significantly reduced after a period of use. Therefore, providing a coating with excellent antiviral and antibacterial properties and the ability to maintain antiviral and antibacterial activity for a long time is of great significance for reducing the risk of people being infected with bacteria or viruses in their daily lives. Summary of the invention

[0003] The purpose of the present invention is to provide an antiviral and antibacterial inorganic interior wall coating and a preparation method thereof, wherein the coating has excellent antiviral and antibacterial activity, durability and alkali resistance.

[0004] According to one aspect of the present invention, an antiviral and antibacterial inorganic interior wall coating is provided, which comprises 20 to 40 parts of silica sol and 0.8 to 1.5 parts of an antiviral and bactericidal preservative, calculated by weight; the antiviral and bactericidal preservative comprises a composite component, and the composite component comprises a triazole compound, an isothiazolinone compound, a thiopyridine oxide compound and a chlorohydroxydiphenyl ether compound.

[0005] The present invention introduces a specific antiviral bactericidal preservative into the coating formula. The triazole compound, isothiazolinone compound, thiopyridine oxide compound and chlorohydroxydiphenyl ether compound in the antiviral bactericidal preservative can play a synergistic role. On the one hand, it has a strong inactivation effect on influenza A virus, enterovirus, polio virus and stubborn viruses that survive on the surface of objects for several weeks. At the same time, it can solve the problem of wall mold, kill mold spores, inhibit their growth, and effectively repair the moldy wall, so that the coating has a strong antiviral and antibacterial function, and solves the problem of wall mold. On the one hand, it solves the problem of poor antiviral and antibacterial activity and durability of coatings in the prior art; on the other hand, it can effectively improve the strong alkali resistance of the coating; and the antiviral and bactericidal preservative has good compatibility and compatibility with other components, which can effectively ensure the stability of the coating; in addition, by reasonably compounding the silica sol with the above-mentioned antiviral and bactericidal preservative, it is beneficial to promote the uniform dispersion of the antiviral and bactericidal preservative in the coating, giving the coating good uniformity and stability, and avoiding the problem of incompatibility of the components in the coating leading to insufficient performance of the antiviral and bactericidal preservative or deterioration of the coating.

[0006] Preferably, the mass ratio of the triazole compound, the isothiazolinone compound, the thiopyridine oxide compound, and the chlorohydroxydiphenyl ether compound is 1:(2-3):(1-2):(1-2). The composite component prepared according to the above ratio has better antiviral and antibacterial activity, durability and alkali resistance.

[0007] Preferably, the triazole compound includes at least one of tebuconazole and diniconazole; the isothiazolinone compound includes 1,2-benzisothiazolin-3-one; the thioxopyridine compound includes 2,2'-dithiobis(pyridine-1-oxide); and the chlorohydroxydiphenyl ether compound includes trichlorohydroxydiphenyl ether. The above-mentioned specific triazole compounds, isothiazolinone compounds, thioxopyridine compounds and chlorohydroxydiphenyl ether compounds can be synergistically matched to further improve the antiviral and antibacterial activity, antiviral and antibacterial durability and strong alkali resistance of the coating.

[0008] Preferably, the antiviral bactericidal preservative includes a capsule core and a capsule wall that wraps the capsule core; the capsule core includes a composite component, the capsule wall includes sodium alginate and modified starch, and the preparation method of the modified starch includes the following operations: gelatinizing the starch, and then adding a composite amylase to the starch after the gelatinization treatment to perform enzymatic hydrolysis and enzyme inactivation in sequence, thereby preparing the modified starch; the composite amylase includes α-amylase, γ-amylase and isoamylase; the pH of the enzymatic hydrolysis treatment is 6.5-7.5 and the temperature is 50-60°C. The modified starch prepared by the above method can be synergistically matched with sodium alginate, so that the capsule wall has good tensile strength and flexibility, which is conducive to the effective embedding of the capsule core, so that the long-term antiviral and antibacterial effect of the antiviral bactericidal preservative is further improved, and at the same time, it is conducive to further optimizing the washability of the coating.

[0009] Preferably, in the composite amylase, the mass ratio of α-amylase, γ-amylase and isoamylase is 1:(3-5):(1-3). By rationally setting the feed ratio of α-amylase, γ-amylase and isoamylase in the composite amylase, it is beneficial to improve the encapsulation ability of the capsule wall, so that the antiviral and antibacterial durability and scrub resistance of the coating are further optimized.

[0010] Preferably, the silica sol is zirconium-modified silica sol, and the preparation method of zirconium-modified silica sol includes the following operations: mixing silica sol with zirconium salt for reaction at 80-90°C, and obtaining zirconium-modified silica sol after the reaction is completed; the zirconium salt includes at least one of zirconium acetylacetonate and zirconium isooctanoate. The above-mentioned organic zirconium salt and the silicon-oxygen bond in the silica sol can form a stable chemical bond, so that the zirconium-modified silica sol has good scrub resistance; moreover, the tetravalent zirconium ions on the surface of the zirconium-modified silica sol can destroy the structure and function of bacteria, and have the effect of inhibiting bacterial growth, so that the zirconium-modified silica sol has excellent antiviral and antibacterial activity.

[0011] Preferably, the mass ratio of zirconium salt to SiO2 contained in silica sol is (0.05-0.5):1.

[0012] Preferably, the antiviral and antibacterial inorganic interior wall coating also includes 12 to 30 parts of water, 10 to 18 parts of titanium dioxide, 10 to 25 parts of filler, 8 to 16 parts of toughening powder, 0.2 to 0.7 parts of cellulose, 0.3 to 0.7 parts of stabilizer, 0.2 to 0.6 parts of dispersant, 0.1 to 0.5 parts of defoaming agent, and 1 to 5 parts of formaldehyde removal aid.

[0013] Preferably, the toughening powder includes Heye Chemical SR-637. The main active ingredient of Heye Chemical SR-637 is a modified composite silicate powder, which can form a dense oxide layer at high temperature, passivate the surface of the substrate, prevent open flame combustion, and improve the fire retardant performance of the coating; on the other hand, the toughening powder has good compatibility with the above-mentioned silica sol, antiviral bactericidal formaldehyde removal agent and other components, which can further improve the stability of the coating.

[0014] Preferably, the stabilizer includes a quaternary ammonium salt. Since the toughening powder is easy to precipitate, by introducing a stable quaternary ammonium salt into the coating, the quaternary ammonium salt can increase the viscosity of the coating, so that the solid particles are more stably dispersed in the coating, and the precipitation, stratification and the like are avoided.

[0015] Preferably, the stabilizer is selected from Heye WJ-100 or Aorun AR-CS1.

[0016] According to another aspect of the present invention, a method for preparing the above-mentioned antiviral and antibacterial inorganic interior wall coating is provided, comprising the following steps: dispersing cellulose in water, and then adding a dispersant, a stabilizer, a defoaming agent, a portion of the silica sol, titanium dioxide, a filler, and a toughening powder in sequence; then adding the remaining silica sol and mixing, and then adding a defoaming agent, a formaldehyde removal aid, and an antiviral and bactericidal preservative in sequence thereto, thereby preparing the antiviral and antibacterial inorganic interior wall coating.

[0017] Preferably, the cellulose comprises hydroxyethyl cellulose selected from Ashland 250 HBR.

[0018] Preferably, the titanium dioxide includes rutile titanium dioxide.

[0019] Preferably, the filler comprises calcined kaolin and 700 mesh calcium carbonate, wherein Ca + ,Mg 2+ The content of calcium and magnesium ions is ≤0.01%. By controlling the content of calcium and magnesium ions to ≤0.01%, the reaction with fillers and potassium silicate in toughening powder to form particles is effectively avoided.

[0020] Preferably, the thickener comprises an acrylate modified copolymer selected from Heye SR-800 or Heye SR-801.

[0021] Preferably, the dispersant comprises a sodium salt, selected from at least one of BASF CX4320, Nopco 5040, and Dow QuickEasy.

[0022] Preferably, the defoaming agent comprises an inorganic silicone defoaming agent. DETAILED DESCRIPTION

[0023] In order to enable those skilled in the art to better understand the technical solutions of the present invention, the technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0024] Example 1

[0025] This embodiment provides an antiviral and antibacterial inorganic interior wall coating, and the preparation method thereof comprises the following steps:

[0026] Step 1: Add hydroxyethyl cellulose to water, adjust the speed to 500rpm / min, and disperse for 5min until the hydroxyethyl cellulose is completely swollen and there are no obvious particles; then add dispersant, stabilizer Heye WJ-100 (the main active ingredient of Heye WJ-100 is quaternary ammonium salt), part of defoamer in turn, stir for 5min, then add 1 / 2 silica sol, disperse evenly, then adjust the speed to 1200rpm / min, add titanium dioxide, filler calcium carbonate, toughening powder Heye Chemical SR-637 (the main active ingredient of Heye SR-637 is modified composite silicate powder) in turn; then adjust the speed to 1500rpm / min, disperse at high speed for 20min, take samples, and measure the fineness with a scraper. The fineness must be less than or equal to 50um.

[0027] Step 2: After the fineness test is qualified, adjust the speed to 500rpm / min, slowly add the thickener on the basis of step 1, stir for 3-5min, then add the remaining amount of silica sol, stir for 5min, then add the remaining defoamer, formaldehyde removal aid, antiviral bactericidal preservative in turn, stir for 5min, thereby preparing the antiviral and antibacterial inorganic interior wall coating.

[0028] The antiviral and antiseptic preservative comprises a capsule core and a capsule wall wrapping the capsule core;

[0029] The capsule core is a composite component, which includes a triazole compound (tebuconazole), an isothiazolinone compound (1,2-benzisothiazolin-3-one), a thiooxidated pyridine compound (2,2'-dithiobis(pyridine-1-oxide)), and a chlorohydroxydiphenyl ether compound (trichlorohydroxydiphenyl ether), and the mass ratio of the triazole compound, the isothiazolinone compound, the thiooxidated pyridine compound, and the chlorohydroxydiphenyl ether compound is 1:2:1:1.

[0030] The capsule wall includes sodium alginate and modified starch. The preparation method of the modified starch is as follows: the starch is dispersed in water, the temperature is raised to 80°C for gelatinization treatment for 10 minutes, then the temperature is lowered to 60°C and the pH value is adjusted to 6.5, and a composite amylase (the composite amylase is compounded by α-amylase, isoamylase, and γ-amylase in a mass ratio of 1:4:2) is added for enzymatic hydrolysis for 4 hours, and the enzyme is inactivated for 30 minutes after the enzymatic hydrolysis is completed. After the enzyme is inactivated, the starch is cooled to room temperature and centrifuged, and the precipitate after centrifugation is collected and dried to obtain the modified starch.

[0031] Among them, the above-mentioned silica sol is zirconium-modified silica sol, and the preparation method of zirconium-modified silica sol is as follows: dissolve zirconium salt zirconium isooctanoate in a solvent to obtain a zirconium salt solution; according to the mass ratio of zirconium salt to SiO2 of 0.1:1, the silica sol and the zirconium salt solution are mixed and reacted at 85°C, and after the reaction is completed, the zirconium-modified silica sol is obtained.

[0032] Table 1. Formula of coating in this example

[0033] Raw material name Mass fraction water 23.18 Silica Sol 30 Titanium dioxide 13 filler 18 Toughening powder 10 Cellulose 0.62 Defoaming agent 0.5 Dispersants 0.6 Wetting Agents 0.2 Stabilizer 0.3 Thickener 0.1 Formaldehyde removal aid 2.5 Antiviral and antiseptic 1

[0034] Example 2

[0035] This embodiment refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds, and chlorohydroxydiphenyl ether compounds in the antiviral and antiseptic preservatives used in this embodiment is 1:2:1:3. In addition to the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0036] Example 3

[0037] This embodiment refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that the mass ratio of triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds, and chlorohydroxydiphenyl ether compounds in the antiviral and antiseptic preservatives used in this embodiment is 1:2:1:0.3. In addition to the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0038] Example 4

[0039] This embodiment refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the process of preparing the antiviral and antiseptic preservative, propiconazole of the same mass is used to replace tebuconazole in Example 1 as the triazole compound of this embodiment. Except for the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0040] Example 5

[0041] This embodiment refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this embodiment and Example 1 is that in the process of preparing the antiviral and antiseptic preservative in this embodiment, 5-chloro-2-methyl-4-isothiazoline-3-one of the same mass is used to replace 1,2-benzisothiazolin-3-one in Example 1 as the isothiazolinone compound of this embodiment. Except for the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0042] Example 6

[0043] This embodiment prepares antiviral and antibacterial inorganic interior wall coatings with reference to embodiment 1. The difference between this embodiment and embodiment 1 is that the capsule wall of the antiviral and antiseptic preservative in this embodiment only includes sodium alginate. In addition to the above differences, the materials and process operations used in this embodiment are strictly consistent with those in embodiment 1.

[0044] Example 7

[0045] This example is used to prepare an antiviral and antibacterial inorganic interior wall coating with reference to Example 1. The difference between this example and Example 1 is that in the process of preparing modified starch in this example, the composite amylase used only includes α-amylase and γ-amylase. In addition to the above differences, the materials and process operations used in this example are strictly consistent with those in Example 1.

[0046] Example 8

[0047] This example is used to prepare an antiviral and antibacterial inorganic interior wall coating with reference to Example 1. The difference between this example and Example 1 is that in the process of preparing modified starch in this example, the composite amylase used only includes α-amylase and isoamylase. In addition to the above differences, the materials and process operations used in this example are strictly consistent with those in Example 1.

[0048] Example 9

[0049] This example is used to prepare an antiviral and antibacterial inorganic interior wall coating with reference to Example 1. The difference between this example and Example 1 is that in the process of preparing modified starch in this example, the mass ratio of α-amylase, isoamylase, and γ-amylase in the composite amylase used is 1:3:5. Except for the above differences, the materials and process operations used in this example are strictly consistent with those in Example 1.

[0050] Example 10

[0051] This example is used to prepare an antiviral and antibacterial inorganic interior wall coating with reference to Example 1. The difference between this example and Example 1 is that in the process of preparing modified starch in this example, the mass ratio of α-amylase, isoamylase, and γ-amylase in the composite amylase used is 1:1:1. Except for the above differences, the materials and process operations used in this example are strictly consistent with those in Example 1.

[0052] Embodiment 11

[0053] This embodiment prepares antiviral and antibacterial inorganic interior wall coatings with reference to Example 1. The difference between this embodiment and Example 1 is that in the process of preparing silica sol, the zirconium-modified silica sol in Example 1 is replaced by the same mass of aluminum-modified silica sol. Except for the above differences, the materials and process operations used in this embodiment are strictly consistent with those in Example 1.

[0054] Example 12

[0055] This embodiment prepares an antiviral and antibacterial inorganic interior wall coating with reference to the embodiment 1. The difference between this embodiment and the embodiment 1 is that in the process of preparing the silica sol, the organic zirconium salt zirconium isooctanoate in the embodiment 1 is replaced by the inorganic zirconium salt ZrOCl2·8H2O of the same mass. Except for the above difference, the materials and process operation used in this embodiment are strictly consistent with those in the embodiment 1.

[0056] Comparative Example 1

[0057] This comparative example refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this comparative example and Example 1 is that in the process of preparing the antiviral and antiseptic preservative in this comparative example, the composite components used only include triazole compounds, isothiazolinone compounds, and thiopyridine oxide compounds. In addition to the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0058] Comparative Example 2

[0059] This comparative example refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this comparative example and Example 1 is that in the process of preparing the antiviral and antiseptic preservative in this comparative example, the composite components used only include triazole compounds, isothiazolinone compounds, and chlorinated hydroxydiphenyl ether compounds. In addition to the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0060] Comparative Example 3

[0061] This comparative example refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this comparative example and Example 1 is that in the process of preparing the antiviral and antibacterial inorganic interior wall coating, the amount of zirconium-modified silica sol in Example 1 is adjusted to 5 parts. In addition to the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0062] Comparative Example 4

[0063] This comparative example prepares an antiviral and antibacterial inorganic interior wall coating with reference to Example 1. The difference between this comparative example and Example 1 is that in the process of preparing the antiviral and antibacterial inorganic interior wall coating, the zirconium-modified silica sol in Example 1 is replaced by SiO2 aerogel of the same mass. Except for the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0064] Comparative Example 5

[0065] This comparative example refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this comparative example and Example 1 is that in the process of preparing the antiviral and antiseptic preservative, the composite component in Example 1 is replaced with tebuconazole of the same mass as the capsule core of this comparative example. In addition to the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0066] Comparative Example 6

[0067] This comparative example refers to Example 1 to prepare an antiviral and antibacterial inorganic interior wall coating. The difference between this comparative example and Example 1 is that in the process of preparing the antiviral and antiseptic preservative, the same mass of 1,2-benzisothiazolin-3-one is used to replace the composite component in Example 1 as the capsule core of this comparative example. In addition to the above differences, the materials and process operations used in this comparative example are strictly consistent with those in Example 1.

[0068] Test Example 1

[0069] 1. Test object:

[0070] The antiviral and antibacterial inorganic interior wall coatings prepared in Examples 1 to 12 and Comparative Examples 1 to 6 were used as test objects in this test example.

[0071] 2. Test method:

[0072] (1) Antiviral and antifungal properties: Refer to T / CNCIA01014-2020 "Antibacterial and Antiviral Coatings" to test the antiviral rate and antifungal level of the coating.

[0073] (2) Washability and alkali resistance: Refer to GB / T9756-2018 "Synthetic resin emulsion interior wall paint" to test the washability and alkali resistance of the paint.

[0074] 3. Test results

[0075] Table 2 Performance test results of coatings in Examples 1 to 12 and Comparative Examples 1 to 6

[0076]

[0077] The test results are shown in Table 2. By comparing the performance test results corresponding to Example 1 with those of Comparative Examples 1-2, 5-6, it can be found that the antiviral and antibacterial activity, durability and alkali resistance of the coatings prepared in Comparative Examples 1-2, 5-6 are lower than those in Example 1. The reason is that under the same conditions of other materials and operations for preparing the coatings, the antiviral and bactericidal preservatives used in Comparative Examples 1-2, 5-6 do not simultaneously include triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds and chlorohydroxydiphenyl ether compounds, and the components are difficult to play a synergistic role, resulting in the deterioration of the antiviral and antibacterial activity, durability and alkali resistance of the coatings.

[0078] By comparing the performance test results corresponding to Example 1 and Comparative Examples 3-4, it can be found that the antiviral and antibacterial activity, durability and alkali resistance of the coatings prepared in Comparative Examples 3-4 are lower than those in Example 1. The reason is that under the same conditions of other materials and operations for preparing the coating, the content of silica sol in Comparative Example 3 is too low and silica sol is not used to prepare the coating in Comparative Example 4, resulting in poor compatibility of the components in the coating, thereby deteriorating the antiviral and antibacterial activity, durability and alkali resistance of the coating.

[0079] The performance test results of Example 1 were compared with those of Examples 2 to 5. As shown in Table 2, under the same conditions of other materials and operations for preparing the coating, the mass ratio of the triazole compound, isothiazolinone compound, thiopyridine oxide compound, and chlorohydroxydiphenyl ether compound in Examples 2 and 3 does not satisfy 1: (2 to 3): (1 to 2): (1 to 2), and in Example 4, propiconazole was used as the triazole compound to prepare the antiviral bactericidal preservative, and in Example 5, 5-chloro-2-methyl-4-isothiazolin-3-one was used as the isothiazolinone compound to prepare the antiviral bactericidal preservative, and the antiviral and antibacterial activity, durability, and alkali resistance of the coating obtained thereby were lower than those in Example 1. This shows that, relative to Examples 2 to 3, Example 1 makes the antiviral and antibacterial activity, durability and alkali resistance of the coating better by reasonably setting the ratio of triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds and chlorohydroxydiphenyl ether compounds; relative to Examples 4 to 5, the specific triazole compounds, isothiazolinone compounds, thiopyridine oxide compounds and chlorohydroxydiphenyl ether compounds in Example 1 can work together to make the antiviral and antibacterial activity, durability and alkali resistance of the coating better.

[0080] The performance test results of Example 1 are compared with those of Examples 6 to 10. As shown in Table 2, under the same conditions of other materials and operations for preparing the coating, the capsule wall of the antiviral bactericidal preservative in Example 6 only includes sodium alginate, and Examples 7 and 8 respectively use only α-amylase and γ-amylase, α-amylase and isoamylase as composite amylases to prepare modified starch, and the mass ratio of α-amylase, isoamylase and γ-amylase in the composite amylases used in Examples 9 and 10 does not meet 1: (3 to 5): (1 to 3), and the antiviral and antibacterial durability and scrubbing resistance of the coating obtained are lower than those of Example 1. This shows that, relative to Examples 6 to 10, Example 1 uses a specific composite amylase to prepare modified starch, and the modified starch and sodium alginate can be synergistically matched, so that the capsule wall has good tensile strength and flexibility, and plays an effective embedding role on the capsule core, thereby making the long-term antiviral and antibacterial ability and scrubbing resistance of the antiviral bactericidal preservative better.

[0081] The performance test results of Example 1 and Examples 11-12 are compared. It can be seen from Table 2 that, under the same conditions of other materials and operations for preparing the coating, Example 11 uses aluminum-modified silica sol as silica sol, and Example 12 uses inorganic zirconium salt to prepare zirconium-modified silica sol, and the scrubbing resistance of the coating obtained is lower than that of Example 1. This shows that, relative to Examples 11-12, Example 1 uses organic zirconium salt to prepare modified zirconium silica sol, and the organic zirconium salt and the silicon-oxygen bond in the silica sol can form a stable chemical bond, so that the zirconium-modified silica sol has good scrubbing resistance, and the tetravalent zirconium ions on the surface of the zirconium-modified silica sol can destroy the structure and function of bacteria and have the effect of inhibiting bacterial growth, thereby making the antibacterial effect and adhesion, scrubbing resistance and stability of the coating better.

[0082] The above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. Although the present invention is described in detail with reference to the above embodiments, ordinary technicians in the relevant field should understand that the technical solutions of the present invention can be modified or equivalently replaced, but these modifications or replacements are all within the protection scope of the present invention.

Claims

1. An antiviral and antibacterial inorganic interior wall coating, characterized in that: Calculated by weight, it includes 20 to 40 parts of silica sol and 0.8 to 1.5 parts of antiviral and bactericidal preservatives; The antiviral and bactericidal preservative comprises a composite component, wherein the composite component comprises a triazole compound, an isothiazolinone compound, a thiopyridine oxide compound and a chlorinated hydroxydiphenyl ether compound.

2. The antiviral and antibacterial inorganic interior wall paint according to claim 1, characterized in that: The mass ratio of the triazole compound, the isothiazolinone compound, the thiopyridine oxide compound, and the chlorohydroxydiphenyl ether compound is 1:(2-3):(1-2):(1-2).

3. The antiviral and antibacterial inorganic interior wall coating according to claim 1 or 2, characterized in that: The triazole compound includes at least one of tebuconazole and diniconazole; The isothiazolinone compounds include 1,2-benzisothiazolin-3-one; The thiooxidized pyridine compounds include 2,2'-dithiobis(pyridine-1-oxide); The chlorinated hydroxy diphenyl ether compounds include trichlorohydroxy diphenyl ether.

4. The antiviral and antibacterial inorganic interior wall paint according to claim 1, characterized in that: The antiviral, bactericidal and preservative agent comprises a capsule core and a capsule wall wrapping the capsule core; The capsule core comprises the composite component, and the capsule wall comprises sodium alginate and modified starch. The preparation method of the modified starch comprises the following operations: gelatinizing the starch, then adding a composite amylase to the gelatinized starch to perform enzymolysis and enzyme inactivation in sequence, thereby preparing the modified starch; the composite amylase comprises α-amylase, γ-amylase and isoamylase; the pH of the enzymolysis treatment is 6.5-7.5 and the temperature is 50-60°C.

5. The antiviral and antibacterial inorganic interior wall paint according to claim 4, characterized in that: In the composite amylase, the mass ratio of the α-amylase, the γ-amylase and the isoamylase is 1:(3-5):(1-3).

6. The antiviral and antibacterial inorganic interior wall paint according to claim 1, characterized in that: The silica sol is zirconium-modified silica sol, and the preparation method of the zirconium-modified silica sol comprises the following operations: The silica sol and the zirconium salt are mixed and reacted at 80-90° C., and the zirconium-modified silica sol is obtained after the reaction is completed; the zirconium salt includes at least one of zirconium acetylacetonate and zirconium isooctanoate.

7. The antiviral and antibacterial inorganic interior wall paint according to claim 1, characterized in that: The antiviral and antibacterial inorganic interior wall paint also includes 12 to 30 parts of water, 10 to 18 parts of titanium dioxide, 10 to 25 parts of fillers, 8 to 16 parts of toughening powder, 0.2 to 0.7 parts of cellulose, 0.3 to 0.7 parts of stabilizers, 0.2 to 0.6 parts of dispersants, 0.1 to 0.5 parts of defoaming agents, and 1 to 5 parts of formaldehyde removal aids.

8. The antiviral and antibacterial inorganic interior wall paint according to claim 7, characterized in that: The toughening powder includes Heye Chemical SR-637.

9. The antiviral and antibacterial inorganic interior wall paint according to claim 8, characterized in that: The stabilizer includes a quaternary ammonium salt.

10. A method for preparing the antiviral and antibacterial inorganic interior wall coating according to any one of claims 1 to 9, characterized in that: The method comprises the following steps: dispersing cellulose in water, and then sequentially adding a dispersant, a stabilizer, a defoamer, a portion of the silica sol, titanium dioxide, a filler, and a toughening powder; then adding the remaining silica sol and mixing, and then sequentially adding a defoamer, a formaldehyde removal aid, and an antiviral and bactericidal preservative thereto, thereby preparing the antiviral and antibacterial inorganic interior wall coating.

Images